AZD2014 + AZD6244
Phase 1/2UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 28/100
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple-Negative Breast Cancer
Conditions
Triple-Negative Breast Cancer, Squamous Cell Lung Cancer, Non-squamous Cell Lung Cancer With KRAS Mutations, Non-squamous Cell Lung Cancer With Wild-type KRAS
Trial Timeline
Jun 1, 2015 → Mar 1, 2020
NCT ID
NCT02583542About AZD2014 + AZD6244
AZD2014 + AZD6244 is a phase 1/2 stage product being developed by AstraZeneca for Triple-Negative Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT02583542. Target conditions include Triple-Negative Breast Cancer, Squamous Cell Lung Cancer, Non-squamous Cell Lung Cancer With KRAS Mutations.
What happened to similar drugs?
1 of 7 similar drugs in Triple-Negative Breast Cancer were approved
Approved (1) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
9
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02583542 | Phase 1/2 | UNKNOWN |
Competing Products
20 competing products in Triple-Negative Breast Cancer